Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samsrita Labs reported zero revenue from operations and zero other income for both Q2 FY26 and H1 FY26, marking another quarter with no business activity. Standalone loss for the quarter widened sharply to Rs 493.50 lakhs versus Rs 6.48 lakhs in the year-ago quarter, while H1 FY26 loss ballooned to Rs 521.16 lakhs from Rs 13.20 lakhs in H1 FY25, translating to an EPS of negative Rs 2.29. Other equity has turned deeply negative at Rs (793.66) lakhs standalone and Rs (732.96) lakhs consolidated, meaning accumulated losses have wiped out shareholder capital. During the quarter, the company raised Rs 3.39 crore via preferential issue to non-promoters, issued 45.5 lakh shares to acquire a 28.62% stake in QROPS Advisory Services via share swap, bought a cancer-drug patent from CLRD for Rs 2 crore by adjusting old deposits, wrote off Rs 2.59 crore of COVID-era CLRD advances, and created a Rs 2.09 crore bad-debt provision against Mangal Savitri Bizcon.
Shareholders should view this as a deeply negative filing: zero top line, rapidly growing losses, and negative net worth signal serious going-concern risks despite the headline-positive operating cash flow of Rs 339 lakhs (driven by working-capital reversals, not earnings). The RPT-heavy restructuring may raise governance red flags, and the stock could face sharp pressure given the erosion of book value per share.